Die Stimmung am IPO-Markt war in der vergangenen Woche ungetrübt. Mit 35 Börsengängen blieb die Emissionstätigkeit unvermindert stark, auch wenn die Dominanz der SPACs (Börsenmantel) ebenso Bestand hatte wie in den Vorwochen.
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient...
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to...
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on...
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical...
